![Simon Lu](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Patrimonio netto: 208 750 $ in data 31/08/2026
Simon Dazhong Lu currently works at Ascentage Pharma Group International Co., Ltd., as Independent Non-Executive Director from 2018.
Dr. Lu also formerly worked at McGill University, as Director from 2016 to 2018, CEL Partners Co. Ltd., as Managing Director from 2008 to 2009, Shanghai NewMargin Ventures Investment Management Co. Ltd., as Partner & Investment Manager from 2002 to 2007, and Arthur Andersen Business Consulting Co. Ltd. (Shanghai), as Auditor.
Dr. Lu received his doctorate degree in 2010 from Nankai University and undergraduate degree in 1991 from Nankai University.
| Società | Data | Numero di azioni | Valutazione | Data di valutazione |
|---|---|---|---|---|
| 20/04/2026 | 48.937 ( 0,01% ) | 208 750 $ | 31/08/2026 |
| Società | Posizione | Inizio |
|---|---|---|
| ASCENTAGE PHARMA GROUP INTERNATIONAL | Direttore/Membro del Consiglio | 06/07/2018 |
| Società | Posizione | Fine |
|---|---|---|
McGill University
 McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Direttore/Membro del Consiglio | 01/11/2018 |
CEL Partners Co. Ltd.
 CEL Partners Co. Ltd. Investment ManagersFinance CEL Partners is an active manager which invests in medium-sized Chinese companies in growing and government-promoted sectors where CEL brings strong industry expertise including environmental (renewable energy, clean transport, energy efficiency, waste recovery , water treatment), healthcare (medical supplies & equipment, OTC/TCM drugs, distribution, CRO services), agribusiness (agriculture machinery, fresh food, green/bio products, logistics/cold-chain/food safety), consumer (FMCG, specialized retail, luxury products, household appliances housing materials and furniture) and suppliers (specialized suppliers such as automotive and aerospace suppliers, automotive parts and services). The firm seeks to invest USD 4-15 million in fast-growing Chinese companies with sales of USD 20-150 million, in Chinese SMEs with development or acquisition plans in Europe and in European SMEs with strong development plans in China. CEL Partners takes minority stakes in their investee companies. They exit investments through trade sales and IPOs. | Amministratore Delegato | 01/07/2009 |
Shanghai NewMargin Ventures Investment Management Co. Ltd.
 Shanghai NewMargin Ventures Investment Management Co. Ltd. Investment ManagersFinance NewMargin is a hands-on, value added manager which invests in high-growth China-based companies in a range of industrial sectors including information technology, healthcare and life sciences, and new material and environmental protection. The firm seeks to invest well managed companies, partnering with entrepreneurs early, sharing their expertise and helping them to execute their business strategies. They provide their investee companies with access to their network of industry experts, entrepreneurs, executives, professional service providers and venture capital funds throughout the world and seek exits in the form of IPOs and trade sales. | Direttore degli Investimenti | 01/12/2007 |
Arthur Andersen Business Consulting Co. Ltd. (Shanghai) | Comptroller/Controller/Auditor | - |
Attive
Inattive
Società nel listino
Aziende private
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
| Aziende private | 6 |
|---|---|
McGill University
McGill University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Shanghai NewMargin Ventures Investment Management Co. Ltd.
Shanghai NewMargin Ventures Investment Management Co. Ltd. Investment ManagersFinance NewMargin is a hands-on, value added manager which invests in high-growth China-based companies in a range of industrial sectors including information technology, healthcare and life sciences, and new material and environmental protection. The firm seeks to invest well managed companies, partnering with entrepreneurs early, sharing their expertise and helping them to execute their business strategies. They provide their investee companies with access to their network of industry experts, entrepreneurs, executives, professional service providers and venture capital funds throughout the world and seek exits in the form of IPOs and trade sales. | Finance |
Nankai University
 Nankai University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CEL Partners Co. Ltd.
CEL Partners Co. Ltd. Investment ManagersFinance CEL Partners is an active manager which invests in medium-sized Chinese companies in growing and government-promoted sectors where CEL brings strong industry expertise including environmental (renewable energy, clean transport, energy efficiency, waste recovery , water treatment), healthcare (medical supplies & equipment, OTC/TCM drugs, distribution, CRO services), agribusiness (agriculture machinery, fresh food, green/bio products, logistics/cold-chain/food safety), consumer (FMCG, specialized retail, luxury products, household appliances housing materials and furniture) and suppliers (specialized suppliers such as automotive and aerospace suppliers, automotive parts and services). The firm seeks to invest USD 4-15 million in fast-growing Chinese companies with sales of USD 20-150 million, in Chinese SMEs with development or acquisition plans in Europe and in European SMEs with strong development plans in China. CEL Partners takes minority stakes in their investee companies. They exit investments through trade sales and IPOs. | Finance |
Arthur Andersen Business Consulting Co. Ltd. (Shanghai) | |
Ascentage Pharma Group International Co., Ltd.
 Ascentage Pharma Group International Co., Ltd. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that engages in discovering, developing and commercializing of therapies for hematological malignancies | Health Technology |
Seleziona la tua edizione
Tutte le informazioni finanziarie adattate in base al livello nazionale
